首页 > 最新文献

Influenza and Other Respiratory Viruses最新文献

英文 中文
Excess All-Cause Mortality by Age and Gender During the COVID-19 Pandemic in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina: 2020–2022
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-26 DOI: 10.1111/irv.70086
Šeila Cilović-Lagarija, Johanna Thea Mølgaard Rantzau, Siniša Skočibušić, Sanjin Musa, Armin Sprečo, Amna Isaković, Mirza Palo, Faris Dizdar, Hidajeta Čolović, Veronica Ivey Sawin, Jens Nielsen, Pernille Jorgensen

Objectives

COVID-19 has had a profound impact on global mortality and morbidity, yet only a fraction of deaths was confirmed and reported. We estimated all-cause excess mortality from 1 January 2020 to 31 December 2022 in the Federation of Bosnia and Herzegovina (FBiH) to assess the true magnitude of the pandemic.

Methods

Data for this analysis was sourced from the FBiH mortality register and supplemented with population statistics and official COVID-19 death counts (i.e., cases where COVID-19 was registered as the cause of death). Using a Poisson model, all-cause excess number of deaths and rates per 100,000 person-years, adjusted for registration delays and stratified by age and gender, were calculated.

Results

FBiH experienced three periods of excess all-cause mortality throughout the first 3 years of the pandemic, with a total of 12,000 excess deaths, highest among adults 45–74 years and males. No excess mortality was observed in children <15 years.

Conclusions

The true mortality impact of COVID-19 in FBiH was substantially higher than the reported deaths, including among younger adults. Strengthening civil registration and vital statistics, including establishment of all-cause mortality surveillance, is essential for improved monitoring of future pandemics and other important public health events. A detailed review of the direct and indirect effects of COVID-19 on mortality should be conducted to identify areas that require more resources, improve health provision and inform mitigation efforts in future pandemics to save lives.

{"title":"Excess All-Cause Mortality by Age and Gender During the COVID-19 Pandemic in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina: 2020–2022","authors":"Šeila Cilović-Lagarija,&nbsp;Johanna Thea Mølgaard Rantzau,&nbsp;Siniša Skočibušić,&nbsp;Sanjin Musa,&nbsp;Armin Sprečo,&nbsp;Amna Isaković,&nbsp;Mirza Palo,&nbsp;Faris Dizdar,&nbsp;Hidajeta Čolović,&nbsp;Veronica Ivey Sawin,&nbsp;Jens Nielsen,&nbsp;Pernille Jorgensen","doi":"10.1111/irv.70086","DOIUrl":"https://doi.org/10.1111/irv.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>COVID-19 has had a profound impact on global mortality and morbidity, yet only a fraction of deaths was confirmed and reported. We estimated all-cause excess mortality from 1 January 2020 to 31 December 2022 in the Federation of Bosnia and Herzegovina (FBiH) to assess the true magnitude of the pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data for this analysis was sourced from the FBiH mortality register and supplemented with population statistics and official COVID-19 death counts (i.e., cases where COVID-19 was registered as the cause of death). Using a Poisson model, all-cause excess number of deaths and rates per 100,000 person-years, adjusted for registration delays and stratified by age and gender, were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>FBiH experienced three periods of excess all-cause mortality throughout the first 3 years of the pandemic, with a total of 12,000 excess deaths, highest among adults 45–74 years and males. No excess mortality was observed in children &lt;15 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The true mortality impact of COVID-19 in FBiH was substantially higher than the reported deaths, including among younger adults. Strengthening civil registration and vital statistics, including establishment of all-cause mortality surveillance, is essential for improved monitoring of future pandemics and other important public health events. A detailed review of the direct and indirect effects of COVID-19 on mortality should be conducted to identify areas that require more resources, improve health provision and inform mitigation efforts in future pandemics to save lives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe”
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-25 DOI: 10.1111/irv.70087

Heemskerk, S., Baliatsas, C., Stelma, F., Nair, H., Paget, J., & Spreeuwenberg, P. Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe. Influenza and Other Respiratory Viruses. 2025; 19(1), e70066.

We apologize for this error.

{"title":"Correction to “Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe”","authors":"","doi":"10.1111/irv.70087","DOIUrl":"https://doi.org/10.1111/irv.70087","url":null,"abstract":"<p>\u0000 <span>Heemskerk, S.</span>, <span>Baliatsas, C.</span>, <span>Stelma, F.</span>, <span>Nair, H.</span>, <span>Paget, J.</span>, &amp; <span>Spreeuwenberg, P.</span> <span>Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe</span>. <i>Influenza and Other Respiratory Viruses.</i> <span>2025</span>; <span>19</span>(<span>1</span>), e70066.\u0000 </p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022)”
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-25 DOI: 10.1111/irv.70084

Conte, D.D., Watanabe, R.A.S., Chaves, A.P.C., Alberto-Lei, F., Perosa, A.H.S., Barbosa, G. and Bellei, N. (2024), Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022). Influenza Other Respi Viruses, 18: e70011, https://doi.org/10.1111/irv.70011.

In the article, the funding information was incomplete.

The funding details read:

This study was supported by FINEP/UFMG/REITORIA/PRPQ (29334)

The funding details should read:

This study was supported by FINEP/UFMG/EDITORIAL/PRPQ (29334) and São Paulo State Research Support Foundation (2023/07391-7).

The online version of the article has been corrected.

We apologize for this error.

{"title":"Correction to “Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022)”","authors":"","doi":"10.1111/irv.70084","DOIUrl":"https://doi.org/10.1111/irv.70084","url":null,"abstract":"<p>\u0000 <span>Conte, D.D.</span>, <span>Watanabe, R.A.S.</span>, <span>Chaves, A.P.C.</span>, <span>Alberto-Lei, F.</span>, <span>Perosa, A.H.S.</span>, <span>Barbosa, G.</span> and <span>Bellei, N.</span> (<span>2024</span>), <span>Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022)</span>. <i>Influenza Other Respi Viruses</i>, <span>18</span>: e70011, https://doi.org/10.1111/irv.70011.\u0000 </p><p>In the article, the funding information was incomplete.</p><p>The funding details read:</p><p>This study was supported by FINEP/UFMG/REITORIA/PRPQ (29334)</p><p>The funding details should read:</p><p>This study was supported by FINEP/UFMG/EDITORIAL/PRPQ (29334) and São Paulo State Research Support Foundation (2023/07391-7).</p><p>The online version of the article has been corrected.</p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age”
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-23 DOI: 10.1111/irv.70088

Curran, D, Matthews, S, Cabrera, ES, et al., The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of Respiratory Syncytial Virus-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age. Influenza Other Respi Viruses. 2024; 18(2):e13236.

In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below.

Desmond Curran 1 |Sean Matthews 2|Eliazar Sabater Cabrera 1 |Silvia Narejos Pérez 3|Lina Pérez Breva 4|Mika Rämet 5|Laura Helman 6|Dae Won Park 7|Tino F. Schwarz 8|Isabel Maria Galan Melendez 9|Axel Schaefer 10|Nathalie Roy 11|Brigitte Stephan 12|Daniel Molnar 1 |Lusine Kostanyan 1 |John H. Powers III 13|Veronica Hulstrøm 1|Members of the AReSVi-006 Study Group

1GSK, Wavre, Belgium

2 Freelance c/o GSK, Wavre, Belgium

3 CAP Centelles, Barcelona, Spain

4 Vaccine Research, FISABIO-Public Health, Valencia, Spain

5 Finnish Vaccine Research, Tampere, Finland

6 MOC Research, Mishawaka, Indiana, USA

7 Korea University Ansan Hospital, Ansan, Republic of Korea

8 Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany

9 Hospital Universitario Fundacion Alcorcon, Madrid, Spain

10 Medizentrum Essen Borbeck, Essen, Germany

11 Medicor Research, Greater Sudbury, Canada

12 SGS proDERM, Schenefeld, Germany

13 Department of Clinical Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA

We apologize for this error.

{"title":"Correction to “The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age”","authors":"","doi":"10.1111/irv.70088","DOIUrl":"https://doi.org/10.1111/irv.70088","url":null,"abstract":"<p>\u0000 <span>Curran, D</span>, <span>Matthews, S</span>, <span>Cabrera, ES</span>, et al., <span>The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of Respiratory Syncytial Virus-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age</span>. <i>Influenza Other Respi Viruses.</i> <span>2024</span>; <span>18</span>(<span>2</span>):e13236.\u0000 </p><p>In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below.</p><p>Desmond Curran <sup>1</sup> |Sean Matthews <sup>2</sup>|Eliazar Sabater Cabrera <sup>1</sup> |Silvia Narejos Pérez <sup>3</sup>|Lina Pérez Breva <sup>4</sup>|Mika Rämet <sup>5</sup>|Laura Helman <sup>6</sup>|Dae Won Park <sup>7</sup>|Tino F. Schwarz <sup>8</sup>|Isabel Maria Galan Melendez <sup>9</sup>|Axel Schaefer <sup>10</sup>|Nathalie Roy <sup>11</sup>|Brigitte Stephan <sup>12</sup>|Daniel Molnar <sup>1</sup> |Lusine Kostanyan <sup>1</sup> |John H. Powers III <sup>13</sup>|Veronica Hulstrøm <sup>1</sup>|Members of the AReSVi-006 Study Group</p><p><sup>1</sup>GSK, Wavre, Belgium</p><p><sup>2</sup> Freelance c/o GSK, Wavre, Belgium</p><p><sup>3</sup> CAP Centelles, Barcelona, Spain</p><p><sup>4</sup> Vaccine Research, FISABIO-Public Health, Valencia, Spain</p><p><sup>5</sup> Finnish Vaccine Research, Tampere, Finland</p><p><sup>6</sup> MOC Research, Mishawaka, Indiana, USA</p><p><sup>7</sup> Korea University Ansan Hospital, Ansan, Republic of Korea</p><p><sup>8</sup> Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany</p><p><sup>9</sup> Hospital Universitario Fundacion Alcorcon, Madrid, Spain</p><p><sup>10</sup> Medizentrum Essen Borbeck, Essen, Germany</p><p><sup>11</sup> Medicor Research, Greater Sudbury, Canada</p><p><sup>12</sup> SGS proDERM, Schenefeld, Germany</p><p><sup>13</sup> Department of Clinical Medicine, George Washington University School of Medicine &amp; Health Sciences, Washington, District of Columbia, USA</p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143475346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of Respiratory Viruses Other Than SARS-CoV-2 in a Large Hospital Laboratory in Rome, Italy, During the Seasons 2016–2017 to 2022–2023
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-20 DOI: 10.1111/irv.70079
Flora Marzia Liotti, Simona Marchetti, Sara D'Onghia, Maurizio Sanguinetti, Rosaria Santangelo, Brunella Posteraro

Background and Objective

Respiratory viruses are major contributors to morbidity and mortality worldwide, with their circulation influenced by seasonal patterns and pandemic-related interventions. This study analyzed detection trends of non-SARS-CoV-2 respiratory viruses in a large Italian hospital over a 7-year period, focusing on variations across COVID-19–related periods and patient age groups.

Methods

We retrospectively analyzed multiplex PCR-based laboratory results of 8836 nasopharyngeal samples collected between September 2016 and August 2023. Viral detection rates were stratified by season, COVID-19–related periods (pre-pandemic, pandemic, post-pandemic), and age groups.

Results

Of the 8836 nasopharyngeal samples analyzed, 2795 (31.6%) tested positive for at least one respiratory virus. Rhinovirus/enterovirus (RV/EV) was the most frequently detected virus (37.6%), followed by influenza A virus (IAV, 17.9%) and respiratory syncytial virus (RSV, 17.2%). The 2020–2021 season had the lowest positivity rate (p < 0.001), with marked declines in IAV and RSV detections, likely because of COVID-19 mitigation measures. Conversely, detections of RV/EV and human coronaviruses increased. Postpandemic data suggested a return to prepandemic patterns, though overall positivity rates remained altered. Age-stratified analysis revealed RSV predominance in infants (p < 0.001), emphasizing its clinical relevance in pediatric populations.

Conclusions

Our findings highlight the dynamic nature of respiratory virus epidemiology and the persistent impact of the COVID-19 pandemic on viral circulation. Continuous surveillance and adaptive public health strategies are essential for managing future outbreaks and mitigating the burden of respiratory viral infections.

{"title":"Detection of Respiratory Viruses Other Than SARS-CoV-2 in a Large Hospital Laboratory in Rome, Italy, During the Seasons 2016–2017 to 2022–2023","authors":"Flora Marzia Liotti,&nbsp;Simona Marchetti,&nbsp;Sara D'Onghia,&nbsp;Maurizio Sanguinetti,&nbsp;Rosaria Santangelo,&nbsp;Brunella Posteraro","doi":"10.1111/irv.70079","DOIUrl":"https://doi.org/10.1111/irv.70079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Respiratory viruses are major contributors to morbidity and mortality worldwide, with their circulation influenced by seasonal patterns and pandemic-related interventions. This study analyzed detection trends of non-SARS-CoV-2 respiratory viruses in a large Italian hospital over a 7-year period, focusing on variations across COVID-19–related periods and patient age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed multiplex PCR-based laboratory results of 8836 nasopharyngeal samples collected between September 2016 and August 2023. Viral detection rates were stratified by season, COVID-19–related periods (pre-pandemic, pandemic, post-pandemic), and age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 8836 nasopharyngeal samples analyzed, 2795 (31.6%) tested positive for at least one respiratory virus. Rhinovirus/enterovirus (RV/EV) was the most frequently detected virus (37.6%), followed by influenza A virus (IAV, 17.9%) and respiratory syncytial virus (RSV, 17.2%). The 2020–2021 season had the lowest positivity rate (<i>p</i> &lt; 0.001), with marked declines in IAV and RSV detections, likely because of COVID-19 mitigation measures. Conversely, detections of RV/EV and human coronaviruses increased. Postpandemic data suggested a return to prepandemic patterns, though overall positivity rates remained altered. Age-stratified analysis revealed RSV predominance in infants (<i>p</i> &lt; 0.001), emphasizing its clinical relevance in pediatric populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings highlight the dynamic nature of respiratory virus epidemiology and the persistent impact of the COVID-19 pandemic on viral circulation. Continuous surveillance and adaptive public health strategies are essential for managing future outbreaks and mitigating the burden of respiratory viral infections.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Analysis of Human Respiratory Syncytial Virus Group B Strains Isolated in Kenya Before and During the Emergence of Pandemic Influenza A/H1N1
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-20 DOI: 10.1111/irv.70082
Julia Wangui, George Gachara, Victor Mobegi, Charles Agoti, James Otieno, Silvanos Opanda, Benjamin Opot, Joseph N. Ngeranwa, Regina Njeru, Wallace Bulimo

Background

We conducted a retrospective study to explore molecular insights into human respiratory syncytial virus (HRSV) group B strains among patients attending outpatient clinics at government medical facilities both prior and during the onset of Influenza A/H1N1/2009 pandemic outbreak.

Methods

We screened 2300 nasopharyngeal swabs using multiplex real time reverse transcriptase polymerase chain reaction. We amplified a segment of the first and second hypervariable regions, as well as the conserved portion of the third domain of the G-gene using HRSV-B specific primers, sequenced by Sanger di-deoxy chain termination method and thereafter analyzed the sequences.

Results

We characterized the circulating strains into three known genotypes: SAB4 (1.4%), BA7 (1.4%), and multiple variants of BA9 (97.2%). The majority of BA9 viruses were uniquely Kenyan with only 4% aligning with BA9 lineages found elsewhere. The mean evolutionary rate of the HRSV-B was estimated to be 3.08 × 10−3 substitutions per site per year.

Conclusion

Our findings indicate that the circulating HRSV-B viruses in Kenya underwent a slower evolution during the period of 2007–2010. Additionally, our findings reveal the existence of a unique lineage as well as new variants that have not been reported elsewhere to date.

{"title":"Molecular Analysis of Human Respiratory Syncytial Virus Group B Strains Isolated in Kenya Before and During the Emergence of Pandemic Influenza A/H1N1","authors":"Julia Wangui,&nbsp;George Gachara,&nbsp;Victor Mobegi,&nbsp;Charles Agoti,&nbsp;James Otieno,&nbsp;Silvanos Opanda,&nbsp;Benjamin Opot,&nbsp;Joseph N. Ngeranwa,&nbsp;Regina Njeru,&nbsp;Wallace Bulimo","doi":"10.1111/irv.70082","DOIUrl":"https://doi.org/10.1111/irv.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We conducted a retrospective study to explore molecular insights into human respiratory syncytial virus (HRSV) group B strains among patients attending outpatient clinics at government medical facilities both prior and during the onset of Influenza A/H1N1/2009 pandemic outbreak.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We screened 2300 nasopharyngeal swabs using multiplex real time reverse transcriptase polymerase chain reaction. We amplified a segment of the first and second hypervariable regions, as well as the conserved portion of the third domain of the G-gene using HRSV-B specific primers, sequenced by Sanger di-deoxy chain termination method and thereafter analyzed the sequences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We characterized the circulating strains into three known genotypes: SAB4 (1.4%), BA7 (1.4%), and multiple variants of BA9 (97.2%). The majority of BA9 viruses were uniquely Kenyan with only 4% aligning with BA9 lineages found elsewhere. The mean evolutionary rate of the HRSV-B was estimated to be 3.08 × 10<sup>−3</sup> substitutions per site per year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings indicate that the circulating HRSV-B viruses in Kenya underwent a slower evolution during the period of 2007–2010. Additionally, our findings reveal the existence of a unique lineage as well as new variants that have not been reported elsewhere to date.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Characteristics of Hospitalized Influenza Patients: An Interim Analysis From the FluHeart Study
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-18 DOI: 10.1111/irv.70067
Kristoffer Grundtvig Skaarup, Filip Soeskov Davidovski, Emil Durukan, Daniel Modin, Mats Christian Højbjerg Lassen, Maria Dons, Anne Marie Reimer Jensen, Niklas Dyrby Johansen, Morten Sengeløv, Frederikke Vyff, Nino Emanuel Landler, Gorm Boje Jensen, Anne Bjerg Nielsen, Jacob Christensen, Raphael Hauser, Peter Schnohr, Rasmus Møgelvang, Lene Nielsen, Jens-Ulrik Stæhr Jensen, Tor Biering-Sørensen

Background

Influenza infection has been associated with multiple cardiac complications including acute heart failure and myocardial infarction. The FluHeart study aims to uncover the potential effect of influenza infection on cardiac structure and function as assessed by echocardiography during hospitalization.

Methods

This prospective cohort study included hospitalized influenza patients of the 2021–2022 influenza season. Participants underwent echocardiography using a prespecified protocol. Participants were successfully matched 1:1:1 on age, sex, and heart failure status with controls from the general population and controls hospitalized with COVID-19.

Results

This interim analysis involved 108 participants (36 influenza patients, 36 general population controls, and 36 COVID-19 patients). Mean age was 72 ± 18 years and 58% were male. Median time from admission to echocardiography was 1 day (IQI: 1:1) for influenza patients. The prevalence of left ventricular (LV) dysfunction was 75%, and right ventricular (RV) dysfunction was observed in 20% of influenza patients. N-terminal pro-brain natriuretic peptide levels were elevated ≥ 300 pg/mL in 62%, and 19% exhibited myocardial injury with elevated high-sensitivity troponin I levels. RV tricuspid annular plane systolic excursion and LV early diastolic peak mitral inflow to early diastolic tissue velocity were significantly worse in influenza patients compared to general population controls. Echocardiographic measures did not significantly differ between patients hospitalized with influenza and COVID-19.

Conclusion

In this interim analysis of the FluHeart study, both RV and LV function measures were significantly impaired in hospitalized influenza patients compared with matched general population controls. The extent of impairment resembled that observed in hospitalized COVID-19 patients.

{"title":"Cardiac Characteristics of Hospitalized Influenza Patients: An Interim Analysis From the FluHeart Study","authors":"Kristoffer Grundtvig Skaarup,&nbsp;Filip Soeskov Davidovski,&nbsp;Emil Durukan,&nbsp;Daniel Modin,&nbsp;Mats Christian Højbjerg Lassen,&nbsp;Maria Dons,&nbsp;Anne Marie Reimer Jensen,&nbsp;Niklas Dyrby Johansen,&nbsp;Morten Sengeløv,&nbsp;Frederikke Vyff,&nbsp;Nino Emanuel Landler,&nbsp;Gorm Boje Jensen,&nbsp;Anne Bjerg Nielsen,&nbsp;Jacob Christensen,&nbsp;Raphael Hauser,&nbsp;Peter Schnohr,&nbsp;Rasmus Møgelvang,&nbsp;Lene Nielsen,&nbsp;Jens-Ulrik Stæhr Jensen,&nbsp;Tor Biering-Sørensen","doi":"10.1111/irv.70067","DOIUrl":"https://doi.org/10.1111/irv.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza infection has been associated with multiple cardiac complications including acute heart failure and myocardial infarction. The FluHeart study aims to uncover the potential effect of influenza infection on cardiac structure and function as assessed by echocardiography during hospitalization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective cohort study included hospitalized influenza patients of the 2021–2022 influenza season. Participants underwent echocardiography using a prespecified protocol. Participants were successfully matched 1:1:1 on age, sex, and heart failure status with controls from the general population and controls hospitalized with COVID-19.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This interim analysis involved 108 participants (36 influenza patients, 36 general population controls, and 36 COVID-19 patients). Mean age was 72 ± 18 years and 58% were male. Median time from admission to echocardiography was 1 day (IQI: 1:1) for influenza patients. The prevalence of left ventricular (LV) dysfunction was 75%, and right ventricular (RV) dysfunction was observed in 20% of influenza patients. N-terminal pro-brain natriuretic peptide levels were elevated ≥ 300 pg/mL in 62%, and 19% exhibited myocardial injury with elevated high-sensitivity troponin I levels. RV tricuspid annular plane systolic excursion and LV early diastolic peak mitral inflow to early diastolic tissue velocity were significantly worse in influenza patients compared to general population controls. Echocardiographic measures did not significantly differ between patients hospitalized with influenza and COVID-19.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this interim analysis of the FluHeart study, both RV and LV function measures were significantly impaired in hospitalized influenza patients compared with matched general population controls. The extent of impairment resembled that observed in hospitalized COVID-19 patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Analysis of Influenza Epidemiology Before and After the COVID-19 Pandemic in Argentina (2018–2019 vs. 2022–2023)
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-17 DOI: 10.1111/irv.70078
Angela Gentile, María del Valle Juárez, Gabriela Ensinck, Oscar Lopez, Pablo Melonari, Tatiana Fernández, Andrés Gioiosa, Gustavo Lazarte, Silvina Lobertti, María Florencia Lucion, Natalia Pejito, Camila Racana, Leandro López, Gabriela Gregorio

Introduction

The COVID-19 pandemic altered the epidemiology of respiratory viruses other than SARS-CoV-2. This study investigated the clinical-epidemiological pattern of hospitalized pediatric patients with acute lower respiratory tract infections (ALRI) and influenza in Argentina, comparing prepandemic and postpandemic periods.

Materials and Methods

This multicenter, cross-sectional study included patients under 18 years old admitted for ALRIs in five tertiary centers of Argentina before (2018 and 2019) and after (2022 and 2023) COVID-19. Changes in viral detection rates, seasonality, and case fatality rate (CFR), along with epidemiological and clinical characteristics, were analyzed. Indirect immunofluorescence assay (IFA) or RT-PCR was used for virological diagnosis pre-pandemic, and only RT-PCR in post-pandemic. Epi Info 7 and SPSS 15.0 was used for data analysis.

Results

A total of 5838 cases of ALRI were included (mean age: 9.5 months; IQR: 4–22 months); 96.6% were tested for viral detection, and 66.4% were positive (3877 cases). Respiratory syncytial virus (RSV) was the most prevalent. Influenza showed typical winter seasonality in 2018, 2019, and 2023. However, 2022 exhibited a bimodal pattern: late summer and spring, with co-circulation of influenza A and B in the second peak. CFR varied by viral diagnosis; influenza showed the highest CFR, all deaths related to influenza A. Among 354 influenza cases, 81% were < 5 years old, 53% were male, 63% had comorbidities, and 14.1% required intensive care. Mean of influenza vaccine coverage (6–24 months) was 21.4%. In both periods, patients with influenza were more likely to have pneumonia. Additionally, in the postpandemic period, malnourishment or being 3 years of age or older was also associated with a higher likelihood of influenza infection compared with infection with other respiratory viruses.

Conclusions

Influenza primarily affected children under 5 years old. Postpandemic cases involved older individuals, and increased circulation of influenza A H3N2 was observed. Vaccination coverage was notably low. Influenza returned to its usual seasonal pattern in 2023.

{"title":"Comparative Analysis of Influenza Epidemiology Before and After the COVID-19 Pandemic in Argentina (2018–2019 vs. 2022–2023)","authors":"Angela Gentile,&nbsp;María del Valle Juárez,&nbsp;Gabriela Ensinck,&nbsp;Oscar Lopez,&nbsp;Pablo Melonari,&nbsp;Tatiana Fernández,&nbsp;Andrés Gioiosa,&nbsp;Gustavo Lazarte,&nbsp;Silvina Lobertti,&nbsp;María Florencia Lucion,&nbsp;Natalia Pejito,&nbsp;Camila Racana,&nbsp;Leandro López,&nbsp;Gabriela Gregorio","doi":"10.1111/irv.70078","DOIUrl":"https://doi.org/10.1111/irv.70078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The COVID-19 pandemic altered the epidemiology of respiratory viruses other than SARS-CoV-2. This study investigated the clinical-epidemiological pattern of hospitalized pediatric patients with acute lower respiratory tract infections (ALRI) and influenza in Argentina, comparing prepandemic and postpandemic periods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This multicenter, cross-sectional study included patients under 18 years old admitted for ALRIs in five tertiary centers of Argentina before (2018 and 2019) and after (2022 and 2023) COVID-19. Changes in viral detection rates, seasonality, and case fatality rate (CFR), along with epidemiological and clinical characteristics, were analyzed. Indirect immunofluorescence assay (IFA) or RT-PCR was used for virological diagnosis pre-pandemic, and only RT-PCR in post-pandemic. Epi Info 7 and SPSS 15.0 was used for data analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 5838 cases of ALRI were included (mean age: 9.5 months; IQR: 4–22 months); 96.6% were tested for viral detection, and 66.4% were positive (3877 cases). Respiratory syncytial virus (RSV) was the most prevalent. Influenza showed typical winter seasonality in 2018, 2019, and 2023. However, 2022 exhibited a bimodal pattern: late summer and spring, with co-circulation of influenza A and B in the second peak. CFR varied by viral diagnosis; influenza showed the highest CFR, all deaths related to influenza A. Among 354 influenza cases, 81% were &lt; 5 years old, 53% were male, 63% had comorbidities, and 14.1% required intensive care. Mean of influenza vaccine coverage (6–24 months) was 21.4%. In both periods, patients with influenza were more likely to have pneumonia. Additionally, in the postpandemic period, malnourishment or being 3 years of age or older was also associated with a higher likelihood of influenza infection compared with infection with other respiratory viruses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Influenza primarily affected children under 5 years old. Postpandemic cases involved older individuals, and increased circulation of influenza A H3N2 was observed. Vaccination coverage was notably low. Influenza returned to its usual seasonal pattern in 2023.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Registry-Based Surveillance of Severe Acute Respiratory Infections in Norway During 2021–2024
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-14 DOI: 10.1111/irv.70080
Elina Seppälä, Håkon Bøås, Jesper Dahl, Jeanette Stålcrantz, Melanie Stecher, Ragnhild Tønnessen, Gunnar Øyvind Isaksson Rø, Hilde Kløvstad, Trine Hessevik Paulsen

Background

In 2021, the Norwegian Institute of Public Health established temporary registry-based surveillance of severe acute respiratory infections (SARI). We aimed to describe the surveillance system and evaluate selected attributes to inform the establishment of a permanent SARI surveillance system.

Methods

SARI cases were defined using ICD-10 discharge codes from national health and administrative registries, including codes for acute upper or lower respiratory infection (URI and LRI), COVID-19, acute respiratory distress syndrome, pertussis or otitis media. Data from polymerase chain reaction (PCR) analyses were available for 10 respiratory pathogens including SARS-CoV-2, influenza virus and respiratory syncytial virus (RSV). We included data from 28 September 2020 to 31 March 2024 and calculated the following parameters: the proportion of cases tested for SARS-CoV-2, influenza virus and/or RSV; time between admission and registration of a SARI-related ICD-10 code; and proportion of cases with URI, LRI and COVID-19.

Results

We identified 214,730 SARI cases, of whom 82%, 73% and 53% were tested for SARS-CoV-2, influenza virus and RSV. Case peaks were predominantly driven by one or a combination of these pathogens. Median time between admission and a registered SARI diagnostic code was 5 (lower–upper quartile 3–10) days. Nowcasting and alternative case definitions for SARI with COVID-19, influenza and RSV improved the timeliness. The ICD-10 codes for LRIs and COVID-19 captured only ~55% of the cases in the age group of 0–29 years compared to the routine case definition, where URIs were included.

Conclusions

Registry-based SARI surveillance provides timely data for handling epidemics of respiratory infections in Norway. We recommend establishing a permanent SARI surveillance system.

{"title":"Registry-Based Surveillance of Severe Acute Respiratory Infections in Norway During 2021–2024","authors":"Elina Seppälä,&nbsp;Håkon Bøås,&nbsp;Jesper Dahl,&nbsp;Jeanette Stålcrantz,&nbsp;Melanie Stecher,&nbsp;Ragnhild Tønnessen,&nbsp;Gunnar Øyvind Isaksson Rø,&nbsp;Hilde Kløvstad,&nbsp;Trine Hessevik Paulsen","doi":"10.1111/irv.70080","DOIUrl":"https://doi.org/10.1111/irv.70080","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In 2021, the Norwegian Institute of Public Health established temporary registry-based surveillance of severe acute respiratory infections (SARI). We aimed to describe the surveillance system and evaluate selected attributes to inform the establishment of a permanent SARI surveillance system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>SARI cases were defined using ICD-10 discharge codes from national health and administrative registries, including codes for acute upper or lower respiratory infection (URI and LRI), COVID-19, acute respiratory distress syndrome, pertussis or otitis media. Data from polymerase chain reaction (PCR) analyses were available for 10 respiratory pathogens including SARS-CoV-2, influenza virus and respiratory syncytial virus (RSV). We included data from 28 September 2020 to 31 March 2024 and calculated the following parameters: the proportion of cases tested for SARS-CoV-2, influenza virus and/or RSV; time between admission and registration of a SARI-related ICD-10 code; and proportion of cases with URI, LRI and COVID-19.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 214,730 SARI cases, of whom 82%, 73% and 53% were tested for SARS-CoV-2, influenza virus and RSV. Case peaks were predominantly driven by one or a combination of these pathogens. Median time between admission and a registered SARI diagnostic code was 5 (lower–upper quartile 3–10) days. Nowcasting and alternative case definitions for SARI with COVID-19, influenza and RSV improved the timeliness. The ICD-10 codes for LRIs and COVID-19 captured only ~55% of the cases in the age group of 0–29 years compared to the routine case definition, where URIs were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Registry-based SARI surveillance provides timely data for handling epidemics of respiratory infections in Norway. We recommend establishing a permanent SARI surveillance system.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in Proportions of Respiratory Syncytial Virus Infections Among Reported Respiratory Tract Infection Cases in Children Aged 0 to 5 Years in Western Pacific and Southeast Asia Regions: A Systematic Review and Meta-Analysis
IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-02-08 DOI: 10.1111/irv.70077
Sangshin Park, Hyelan Lee, Jung Yoon Park, Sujin Choi, Hyun Jung Kim, Lorenzo Bertizzolo, Young Hwa Lee, Young June Choe

Background

Respiratory syncytial virus (RSV) is an important cause of bronchiolitis and pneumonia in children globally. This study aimed to incorporate new data to update estimates of RSV burden in children through 5 years of age in Western Pacific and Southeast Asia Regions.

Methods

A systematic review and meta-analysis were conducted to examine the proportion of RSV among cases of respiratory tract infection (RTI) in children in Western Pacific and Southeast Asia Regions using random effects models. Studies were eligible if they met the following inclusion criteria: (1) observational studies such as cohort and cross-sectional studies; (2) studies on humans; (3) studies on patients with RTI or influenza-like illness (ILI); (4) studies reporting incidence or proportion of RSV infection among respiratory related illness; and (5) studies on children aged 5 years or less.

Findings

A total of 4403 studies were identified from an initial search. After screening titles, abstracts, and full-text review, a total of 173 studies that met predefined eligibility criteria were included in the analysis. The overall proportion of RSV infections among all ARTIs was 18.7% (95% CI: 16.0%–21.5%), whereas the proportion of RSV infections among LRTIs was 28.7% (95% CI: 2.6%–30.3%) in children in Western Pacific and Southeast Asia Regions between 1970 and 2020. The proportion of RSV infections peaked in the 1980s at 33.4% (95% CI: 19.8%–48.5%), having increased from 10.6% (95% CI: 2.9%–22.2%) in the 1970s. It then showed a decreasing trend, with 28.9% (95% CI: 18.8%–40.3%) in the 1990s, 24.5% (95% CI: 22.3%–26.8%) in the 2000s, and 20.1% (95% CI: 17.8%–22.5%) in the 2010s. By country, Myanmar (50.0%; 95% CI, 47.5%–52.4%) and New Zealand (45.3%; 95% CI, 37.1%–53.7%) had the highest proportion during the overall time period, followed by Bhutan (45.2%; 95% CI, 36.4%–54.3%), Lao PDR (41.0%; 95% CI, 36.2%–46.0%), and Vietnam (35.5%; 95% CI, 19.3%–53.6%).

Interpretation

Substantial RSV-associated disease burden occurs in children in Western Pacific and Southeast Asia Regions. Our findings provide new and important evidence of the need for RSV prevention in Western Pacific and Southeast Asia countries. They could inform future preventive policy.

{"title":"Trends in Proportions of Respiratory Syncytial Virus Infections Among Reported Respiratory Tract Infection Cases in Children Aged 0 to 5 Years in Western Pacific and Southeast Asia Regions: A Systematic Review and Meta-Analysis","authors":"Sangshin Park,&nbsp;Hyelan Lee,&nbsp;Jung Yoon Park,&nbsp;Sujin Choi,&nbsp;Hyun Jung Kim,&nbsp;Lorenzo Bertizzolo,&nbsp;Young Hwa Lee,&nbsp;Young June Choe","doi":"10.1111/irv.70077","DOIUrl":"https://doi.org/10.1111/irv.70077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Respiratory syncytial virus (RSV) is an important cause of bronchiolitis and pneumonia in children globally. This study aimed to incorporate new data to update estimates of RSV burden in children through 5 years of age in Western Pacific and Southeast Asia Regions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review and meta-analysis were conducted to examine the proportion of RSV among cases of respiratory tract infection (RTI) in children in Western Pacific and Southeast Asia Regions using random effects models. Studies were eligible if they met the following inclusion criteria: (1) observational studies such as cohort and cross-sectional studies; (2) studies on humans; (3) studies on patients with RTI or influenza-like illness (ILI); (4) studies reporting incidence or proportion of RSV infection among respiratory related illness; and (5) studies on children aged 5 years or less.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>A total of 4403 studies were identified from an initial search. After screening titles, abstracts, and full-text review, a total of 173 studies that met predefined eligibility criteria were included in the analysis. The overall proportion of RSV infections among all ARTIs was 18.7% (95% CI: 16.0%–21.5%), whereas the proportion of RSV infections among LRTIs was 28.7% (95% CI: 2.6%–30.3%) in children in Western Pacific and Southeast Asia Regions between 1970 and 2020. The proportion of RSV infections peaked in the 1980s at 33.4% (95% CI: 19.8%–48.5%), having increased from 10.6% (95% CI: 2.9%–22.2%) in the 1970s. It then showed a decreasing trend, with 28.9% (95% CI: 18.8%–40.3%) in the 1990s, 24.5% (95% CI: 22.3%–26.8%) in the 2000s, and 20.1% (95% CI: 17.8%–22.5%) in the 2010s. By country, Myanmar (50.0%; 95% CI, 47.5%–52.4%) and New Zealand (45.3%; 95% CI, 37.1%–53.7%) had the highest proportion during the overall time period, followed by Bhutan (45.2%; 95% CI, 36.4%–54.3%), Lao PDR (41.0%; 95% CI, 36.2%–46.0%), and Vietnam (35.5%; 95% CI, 19.3%–53.6%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Substantial RSV-associated disease burden occurs in children in Western Pacific and Southeast Asia Regions. Our findings provide new and important evidence of the need for RSV prevention in Western Pacific and Southeast Asia countries. They could inform future preventive policy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Influenza and Other Respiratory Viruses
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1